ホーム › がん（全種類） › テネシー › Nashville
Nashville、TNにおけるがん（全種類）の臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、がん（全種類）に関する65件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第2/3相
- SCRI Oncology Partners /ID# 276959, Nashville
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
被験者募集中第2相
- SCRI Oncology Partners /ID# 279733, Nashville
A Study of ASP3082 in Adults With Advanced Solid Tumors
被験者募集中第1相
- Vanderbilt University Medical Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
被験者募集中第3相
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
被験者募集中第1相
- PHN-012-001 Site, Nashville
Registry Study for Radiation Therapy Outcomes
被験者募集中観察研究
- Tennessee Oncology Proton Center, Franklin · 17マイル先
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
被験者募集中観察研究
- Vanderbilt University Medical Center, Nashville
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
被験者募集中第1相
- GSK Investigational Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
被験者募集中観察研究
- Vanderbilt University Medical Center, Nashville
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
被験者募集中第2/3相
- Henry-Joyce Cancer Clinic, Nashville
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
被験者募集中第1相
- Sarah Cannon Cancer Institute, Nashville
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
被験者募集中第3相
- Sarah Cannon Research Institute, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Study of JNJ-87890387 for Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
被験者募集中第3相
- Vanderbilt University Medical Center, Nashville
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
被験者募集中第3相
- Quetzal Site 12, Nashville
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
被験者募集中第3相
- SCRI Oncology Partners /ID# 279779, Nashville
- Vanderbilt University Medical Center /ID# 280169, Nashville
Pan Tumor Rollover Study
被験者募集中第2相
- Tennesse Oncology, Nashville
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
被験者募集中第3相
- SCRI Oncology Partners ( Site 7000), Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institue, Nashville
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
被験者募集中第2/3相
- Sarah Cannon Research Inst, Nashville
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
被験者募集中第1/2相
- GSK Investigational Site, Nashville
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Center, Nashville
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
被験者募集中第3相
- Research Site, Nashville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Tennessee Oncology, Nashville
- USO - US Oncology Research Network, Nashville
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
被験者募集中観察研究
- Vanderbilt University, Nashville
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
被験者募集中第3相
- Tennessee Oncology PLLC - Chattanooga, Nashville
- Tennessee Oncology, PLLC, Nashville
- Vanderbilt University Medical Center, Nashville
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center at Franklin, Franklin · 17マイル先
- 他1件
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Sara Cannon Research Institute Tennessee, Nashville
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
被験者募集中第2相
- SCRI Oncology Partners /ID# 274522, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
被験者募集中第2相
- Vanderbilt University, Ingram Cancer Center, Nashville
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
被験者募集中第1/2相
- Tennessee Oncology, Nashville
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
被験者募集中早期第1相
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
被験者募集中第1相
- GSK Investigational Site, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
被験者募集中第1相
- Sarah Cannon, SCRI Oncology Partners, Nashville
CT-95 in Advanced Cancers Associated With Mesothelin Expression
被験者募集中第1相
- Context Investigational Site, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Nashville
Galleri® in the Medicare Population.
被験者募集中健康なボランティア歓迎
- HCA Healthcare Centennial, Nashville
- HCA Healthcare Nashville, Nashville
- HCA Healthcare Brentwood, Brentwood · 9マイル先
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
被験者募集中第1相
- GSK Investigational Site, Nashville
Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
被験者募集中第1相
- Vanderbilt University Medical Center, Nashville
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
被験者募集中早期第1相
- Vanderbilt University Medical Center, Nashville
High-Resolution PET-CT Imaging for Surgical Margin Visualization
被験者募集中
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
Suprachoroidal Administration in Subjects With Metastases to the Choroid
被験者募集中第2相
- Tennessee Retina, PC, Nashville
A Study of YL242 in Subjects With Advanced Solid Tumors
被験者募集中第1/2相
- US-205, Nashville
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
被験者募集中第1相
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
Inherited CAncer REgistry
被験者募集中観察研究健康なボランティア歓迎
- Vanderbilt-Ingram Cancer Center, Nashville
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
被験者募集中第1/2相
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
被験者募集中観察研究
- Provision CARES Proton Therapy Nashville, Franklin · 17マイル先
他の都市におけるがん（全種類）の試験
- Houston, TX121件の研究
- New York City, NY109件の研究
- Boston, MA85件の研究
- Los Angeles, CA74件の研究
- Philadelphia, PA59件の研究
- Washington, DC58件の研究
- Durham, NC58件の研究
- Chicago, IL51件の研究
- Atlanta, GA49件の研究
- Seattle, WA49件の研究
- Arlington, VA48件の研究
- St. Louis, MO46件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 転移性癌70件の研究
- 大腸癌69件の研究
- 卵巣がん49件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 悪性黒色腫33件の研究
- 多発性骨髄腫32件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。